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Summary In this study 125 primary lung tumours have been immunostained with a panel of 5 anti-p53
antibodies (PAb240, PAb421, PAbl801, CM-1 and C19). These antibodies recognise different epitopes over the
full extent of the p53 gene. It is generally believed that immunolabelling identifies only mutant p53 proteins
due to the short half life of the wild type protein. The aims of this study were to confirm earlier studies ofp53
positivity in human lung tumours and to establish whether or not this bore any relationship to survival.
Immunostaining was demonstrated within the nuclei of affected cells in 54% of the 125 lung tumours (59%
of 78 squamous cell carcinomas, 52% of 42 adenocarcinomas and 20% of five small cell carcinomas). This
confirms previous smaller studies of p53 protein expression in human lung tumours.
Survival curves have been drawn for all of the cases considered together and for squamous and adenocar-
cinomas separately. No differences in survival between p53 positive and negative cases were seen for any group
of tumours. This indicates that although p53 may be of considerable importance in the initiation of
malignancy it is probably of little significance once a tumour has developed.
Primary lung cancer is now recognised as a major cause of
premature death in the world and is mainly related to
cigarette smoking. At the cellular level the mechanism of its
origin is unknown. Research is currently focusing heavily
upon p53, a 53kD nuclear phosphoprotein, first demon-
strated by its ability to bind the SV40 large tumour (T)
antigen (Lane & Crawford, 1979) and subsequently found in
non-virally transformed cells.
The p53 gene is located on band 13p of chromosome 17
and is mutated or deleted in a high proportion (usually more
than 50%) of tumours. The most frequently observed genetic
alterations in lung cancer are base transversions from G to T
(Nigro et al., 1989), thought to be caused by carcinogens
such as benzopyrene, a major constituent of cigarette smoke.
Complete missense mutations are produced, as the transver-
sions tend to occur in regions of highly evolutionary con-
served amino acids; the mutant p53 not only loses its normal
functioning but may acquire new, potentially oncogenic,
activity.
The normal function of p53 is unclear, but its structure
suggests that it is a DNA-binding transcription activator,
acting in conjunction with an accessory protein (O'Rouke et
al., 1990). The subsequent protein products are believed to
exert negative control on the cell cycle, regulating passage
into the S phase of DNA replication (Mercer et al., 1984).
Thus an abnormally low level of wild-type p53 results in a
deficiency of the regulatory proteins, allowing largely uncon-
trolled cell division.
Mutations of p53 alone are not sufficient for tumour for-
mation (Purdie et al., 1991), but do represent the most
common genetic abnormality in lung cancer and a vital step
in the progression towards malignancy. Reduction to homo-
zygosity (additional loss of the wild-type allele) is a common
secondary feature of tumorigenesis (Bartek et al., 1990);
mutant p53 can also bind to the wild-type protein and inac-
tivate it, or prevent transcription from the normal gene (Her-
showitz, 1987).
Conversion of p53 from the normal to mutant phenotype
alters its histochemical characteristics, since the half-life of
the protein is enhanced from 6-20 min to several hours
(Gannon et al., 1990). Mutant p53 has also been shown to
bind to cellular proteins such as hsp70, a member of the heat
shock protein family (Pinhasi et al., 1986), which increases its
stability and can explain the unusual occurrence ofp53 in the
cytoplasm. These two effects lead to a vast increase in the
amount of p53 in affected cells, which can be detected via
antibodies against various epitopes.
Immunohistochemical staining uses the excessive amounts
of p53 as a marker for mutation, since normal cellular levels
are far too low to be detected. A previous study of lung
tumours (Iggo et al., 1990) examined 47 cases and found
that 60% of the tumours stained positively for p53. Our aim
was to extend the study to 125 cases of primary lung
tumours and also to see if any correlation could be found
between p53 over-expression and survival. Should a link be
found between p53 expression and survival in lung cancer,
the staining procedure could prove to be a valuable diagnos-
tic indicator and might assist in the selection of appropriate
therapy.
In this study we have examined 125 primary lung cancers
of the major histological types and stained them with a panel
of antibodies for the presence of elevated levels of p53. The
results have then been analysed with respect to patient sur-
vival and tested statistically for any correlation between p53
expression and survival.
Materials and methods
Lung specimens
One hundred and twenty-five tumours were received immed-
iately after removal as lung resection specimens from the
operating theatre. These comprised tumours from patients
undergoing radical pulmonary resection for carcinoma of the
lung in Oxford and for whom satisfactory clinical data could
be obtained. They were collected between 1984 and 1988,
with a mean follow-up period of 31.5 months; 49% of the
patients had died by the end of the study (96% of whom
were assumed to have died of their disease).
Histological classification and differentiation were assessed
by light microscopy independently prior to immunocyto-
chemical staining. Tumours were classified as small cell (five
cases), squamous cell (78 cases) and adenocarcinoma (40
cases) according to the predominant cell type seen on light
microscopy as described previously by the authors (Dunnill
& Gatter, 1986).
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All tissue was frozen in liquid nitrogen and stored at
- 70°C until required. 8 iLm cryostat sections were taken
from each tumour and dried overnight to improve cellular
morphology, prior to fixation in acetone for 10 min. Sections
were either used immediately or stored at - 20°C.
The primary antibodies (see Table I) were applied to the
dry tissue sections and incubated in a moist chamber for
30 min. The sections treated with polyclonal antibodies were
then incubated with hybridoma supernatant from a mouse
monoclonal antibody against rabbit immunoglobulins. Rab-
bit-anti-mouse immunoglobulins and then pre-formed anti-
alkaline phosphatase (APAAP) complexes were then added
to all sections, initially for 30 min each and then for a further
Omin to intensify the staining reaction. The sections were
washed in Tris-buffered saline (TBS) between every stage.
Staining was achieved by the APAAP method (Cordell et
al., 1984), followed by counterstaining with haematoxylin.
Control sections for each tumour had the primary antibodies
omitted. Two authors (RM & IK) made separate microscopic
examinations of all slides, noting the presence of nuclear
positivity; this was done independently and results were com-
pared afterwards. Positive staining of less than 10%, or very
weak diffuse staining was considered negative.
Survival curves were plotted using the method of Kaplan
and Meier (Kaplan & Meier, 1958) with statistical
significance calculated using the log rank test (Peto et al.,
1977).
Results
Significant positive staining was detected in 70 of the 125
tumour specimens examined (54%). In spite of the long
storage of many of the specimens no deterioration in the
quality of staining could be detected. The results for the
different histological types are shown in Table II.
Positive staining was found to be a predominantly nuclear
phenomenon (Figure 1), although some cells showed slight
traces of reactivity within the cytoplasm. A few nuclei dem-
onstrated unusual granular positivity, in an otherwise nega-
tive case; such positivity was disregarded.
The intensities of staining resulting from the different
antibodies varied greatly but consistently. CM-1, PAbl801
and C19 all produced quite intense staining, whilst PAb421
and PAb24O were much weaker (Figure 2), with only a few
cases showing strong, clear positivity. Positive staining was
generally most intense around the periphery of each tumour
island, although several cases showed very patchy positivity,
in which scattered cells throughout the island were stained.
Survival graphs of all cases and squamous or adenocar-
cinomas separately showed parallel curves with no statistical
difference between negative and positive cases (Figure 3). The
survival curves were also plotted for individual antibodies.
Again as above there were no statistically significant
differences. (Figure 3).
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Figure 1 Detail of squamous cell carcinoma of the lung which
showed strong homogenous expression of p53 protein expression
with all 5 monoclonal antibodies used in this study. a, antibody
PAbl8O0 and b, antibody C19 illustrate the range of staining
intensity seen.
Discussion
Mutations of the p53 gene were first implicated in tumori-
genesis in 1985 when Jenkins et al. (Jenkins et al., 1985)
discovered that the transforming activity of p53 in the
murine system was enhanced following mutation of its amino
acid sequence. Subsequently it has been declared the most
frequently mutated tumour suppressor gene in human tu-
mours. A previous study of lung tumours (Iggo et al., 1990)
Table I Antibodies used in this study
Position of recognised
Antibody epitope on P53 protein Ref/source
Monoclonal:
PAbl8O1 between amino acids 32 and 79 (Banks et al., 1986)
PAb240 between amino acids 156 and 335 (Gannon et al., 1990)
PAb421 between amino acids 370 and 378 (Harlow et al., 1981)
Polyclonal:
CM-I both recognise a number of David Lane
Cl9 different sites on the protein David Lane
Table II Summary of results
Tumour type No. of specimens No. positive (%) No. negative (%)
SQC 78 46 (59) 32 (41)
ADC 42 21 (50) 21 (50)
SCC 5 1 (20) 4 (80)P53 IMMUNOSTAINING IN LUNG CANCER 737
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Figure 2 An adenocarcinoma of the lung which showed variable
staining with the panel of antibodies ranging from strong homo-
geneous positivity with antibody PAb 1801 a, down to virtual
negativity with antibody PAb 421 b.
examined 47 cases and found that 60% of the tumours
stained positively for p53. Our aim was to extend the study
to 125 cases of primary lung tumours and also to see if any
correlation could be found between p53 over-expression and
survival.
We found that 54% of the tissue samples stained positively
for p53, indicating the presence of excessive levels of the
protein; abnormal levels are the result of p53 stabilisation,
which is believed only to occur with a mutated protein. This
percentage confirms our earlier study (Iggo et al., 1990) and
compares favourably with the results from another smaller
study on lung tumours (50% (Caamano et al., 1991)) and
with work on breast (45.5%) (Cattoretti et al., 1988), colorec-
tal (55%) (Van Den Berg et al., 1989) and (42%) (Scott et
al., 1991) and ovarian cancer (50%) (Marks et al., 1991).
However, it is important to recognise that there could be
many tumours which are deficient in wild-type p53, yet do
not register as positive in our study. The most likely abnor-
mality in such cases is the loss of both alleles for p53 (Mowat
et al., 1985), so that neither wild-type nor mutant p53 is
expressed. Alternatively a mutation could occur that pro-
duces a p53 molecule which is not recognized by any of the
five antibodies in our panel. Yewdell et al. (1986) have also
described the phenomenon of selective p53 phosphorylation
and protein complexing in tumour cells, which may con-
ceivably have significant effects upon epitope availability.
Our results showed that from a sample of 125 lung
tumours, there was no statistically significant correlation
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Figure 3 Survival curves for p53 protein expression for a, all
lung tumours b, squamous cell carcinomas c, adenocarcinomas of
the lung.
between the level of expression of mutant p53 proteins and
patient survival, either for the entire range of tumours or for
specific histological types. In a study of 51 non-small cell
tumours (Chiba et al., 1990) no significant association could
be found with tumour stage, nodal status or histological
type. Although no survival data were given these results
support the findings of the present study. Correlations be-
tween p53 and survival have been reported on two occasions
in breast cancer (Cattoretti et al., 1988; Thompson et al.,
1990), although in the case of Cattoretti (Cattoretti et al.,
1988) it appears to be merely an association between mutant
p53 and the expression of another protein, rather than intrin-
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sically linking p53 to survival. Scott (Scott et al., 1991) found
a link in colorectal cancer between p53 expression and cell
proliferation, indicating that a deficiency of wild-type p53
may prevent dividing cells from becoming quiescent. This
would maintain an excessive number of cells in the dividing
pool, conceivably enhancing the aggression of the tumour.
However, despite such a finding, Scott (Scott et al., 1991) was
also unable to link p53 statistically with survival (negative
Dukes test result). Furthermore, although they used only one
antibody, Ostrowski et al. (Ostrowski et al., 1991) couldn't
show any correlation between labelling and survival in breast
tumours.
The consistent lack of positive correlations suggests that
although p53 is of considerable importance in the initiation
of tumours in a wide variety of tissues, the nature of the
particular oncogene involved initially is probably of little
significance once a tumour has developed (although this may
be proven wrong in future molecular studies on a variety of
p53 mutations). We can conclude that in lung cancer the
level of expression of p53 does not significantly affect the
length of patient survival and is therefore at present of no
use as a diagnostic indicator for this disease.
However, it is likely that once a tissue has become can-
cerous, the probability of survival is not decreased by over-
expression of p53, since those tumours indicated as negative
for p53 will presumably have a mutation in another gene,
leading to enhanced cell division by other means. Thus once
a tissue is cancerous, the particular oncogene involved init-
ially will probably play little part in the prognosis. It should
also be remembered that unlabelled tumours may also con-
tain gross abnormalities in p53 expression since the causative
cell could feasibly have possessed a double deletion of the
p53 allele.
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